Therapies

Tbo-filgrastim

Neutroval

This post is under:

Oncofocus Test Kit
includes suggestions for Tbo-filgrastim

Oncofocus is the world’s most comprehensive precision oncology test that precisely identifies the right drug for your cancer thereby increasing your chances of successful treatment.

Discover Oncofocus Today Do you want to order now? Request a test.

SUMMARY

Company: Teva Pharmaceutical
Approval Status: FDA Approved August 2012
Specific Treatments: severe chemotherapy-induced neutropenia
Drug: Tbo-filgrastim

 

GENERAL INFORMATION

Neutroval is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation commitment and some end-cell functional activation, which increases neutrophil counts and activity.

It is specifically approved to reduce the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

It is supplied as a solution for subcutaneous injection. The recommended dose of tbo-filgrastim is 5 mcg/kg per day administered as a subcutaneous injection. Administer the first dose of tbo-filgrastim no earlier than 24 hours following myelosuppressive chemotherapy. Do not administer tbo-filgrastim within 24 hours prior to chemotherapy.

 

CLINICAL RESULTS

FDA Approval

The FDA approval was based on a multinational, multicenter, randomized and controlled study in 348 chemotherapy-naive subjects with high-risk stage II, stage III, or stage IV breast cancer receiving doxorubicin (60 mg/m2) and docetaxel (75 mg/m2). The trial compared tbo-filgrastim to placebo and a non-US-approved filgrastim product as controls. Tbo-filgrastim, placebo, and the non-US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy for at least five days and continued to a maximum of 14 days or until an ANC of >10,000×106/L after nadir was reached. Tbo-filgrastim was superior to placebo in duration of severe neutropenia, with a statistically significant reduction in duration (1.1 days versus 3.8 days; p < 0.0001).

 

SIDE EFFECTS

Adverse events associated with the use of may include, but are not limited to, the following:

  • bone pain
  • leukocytosis

 

MECHANISM OF ACTION

Neutroval is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation commitment and some end-cell functional activation, which increases neutrophil counts and activity.

 

LITERATURE REFERENCES

Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. Journal of Thoracic Oncology : official publication of the International Association for the Study of Lung Cancer. 2009 Jun;4(6):736-40

del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC cancer 2008 Nov 12;8:332

Source: centerwatch